Polio or poliomyelitis is a disabling and life-threatening disease caused by poliovirus (PV), a nonenveloped, positive-sense single-stranded RNA virus classified in the genus Enterovirus in the family Picornaviridae, of which there are three wild serotypes: PV 1–3. As a consequence of global polio vaccination efforts, wild PV serotypes 2 and 3 have been eradicated around the world, and wild PV serotype 1-transmitted cases have been largely eliminated except for limited regions. However, vaccine-derived PV, pathogenically reverted live PV vaccine strains, has become a serious issue. For the global eradication of polio, the World Health Organization (WHO) is conducting the third edition of the Global Action Plan (GAPIII). The WHO GAPIII rationalizes that with the use of inactivated PV vaccines, most countries will have no need to retain live PV in the post-eradication and post-OPV era, and that facility-associated risks can be eliminated by destruction of all wild PV and OPV infectious and potentially infectious materials. However, when PV-susceptible cells are used to isolate non-PV viruses for public health purposes in countries or regions with wild PV- and/or OPV-derived cases, the resultant cell culture has to be handled as potentially infectious, making it a costly and laborious burden.

The Vero cell line is a continuous cell line established from the kidney of the Chlorocebus sabaeus species (or the sabaeus subspecies of C. aethiops) of African green monkeys (AGMs), the whole genome sequences of which have been determined in several sublines. Vero cells are highly susceptible to various viruses, including PV, partly because of the loss of the type I interferon gene cluster by a homozygous ~9-Mb deletion on chromosome 12. Since Vero cells are incapable of producing any type I interferons, they do not execute anti-viral pathways downstream of the interferon receptor in host cells in response to viral infection; however, they have the functional interferon receptor. Therefore, they have been successfully used as a first-choice cell model for various types of life-threatening emerging pathogens. Vero cells are also frequently used as a cell substrate for human virus vaccines because of their non-tumorigenicity.

To provide an ideal replacement of standard Vero cells to isolate emerging/re-emerging viruses without the risk of generating PV-infected materials, we here generated a PV-nonsusceptible Vero cell subline by disrupting genomic genes encoding AGM paralogs of the human PV receptors.
Results and discussion

Genomic genes and cDNAs of the human PV receptor homologs in Vero cells. The cell receptor of PV (PVR; also known as CD155) is a glycosylated membrane protein with an N-terminal extracellular domain, single transmembrane domain, and C-terminal cytoplasmic domain (Fig. 1a). The human genome has only one PVR-encoding gene, which expresses four alternative splicing transcripts. Among the transcript variants, only two variants have the transmembrane domain and function as the cell receptor of PV1. The AGM genome contains two paralogs of the human PVR20,21, hereafter referred to as PVR1 and PVR2, which probably arise because of gene duplication. A previous study showed that both AGM PVRs have the potential to form functional PVRs21.

In both genes, the first exon encodes the translational initiation codon, the signal peptide domain, and a part of the extracellular immunoglobulin-like V-type domain, which is essential for functional PVR1,22. We amplified the first exon and flanking introns of the PVRs in the Vero JCRB9013 cell line (which is equivalent to the Vero ATCC CCL-81 cell line) by genomic polymerase chain reaction (PCR), and sequenced them to design guide RNA (gRNA) targeting this exon. The amplified region of the PVR2 gene of Vero cells was found to contain synonymous single nucleotide variations (SNVs) when compared with counterparts in AGM reference sequences (Panel b). Additionally, we obtained several full-length cDNA clones of Vero cell PVR1 and PVR2.
Disruption of PVR1, PVR2, or both in Vero cells. Following the scheme shown in Fig. 2a, we constructed PVR-disrupted Vero cell lines, obtaining two PVR1 single-knockouts (SKOs), two PVR2 SKOs, and six PVR1/PVR2 double-knockouts (DKOs) (Supplementary Fig. 2). Among the PVR1/PVR2 DKO cell clones, two clones (ΔPVR1/2−1 and ΔPVR1/2−2) were derived from a PVR1 SKO clone (ΔPVR1-1) while four clones (ΔPVR1/2−3, ΔPVR1/2−4, ΔPVR1/2−5, and ΔPVR1/2−6) were derived from another PVR1 SKO clone (ΔPVR1-2; Supplementary Fig. 2). No obvious morphological changes were observed among these clones (Fig. 3a). Nevertheless, the ΔPVR1-2 cell clone had retarded entry into the logarithmic phase of cell growth after plating, when compared with the parental, ΔPVR1-1, ΔPVR2-1, and ΔPVR2-2 cell clones (Fig. 3b). Thus, we chose ΔPVR1-1, not ΔPVR1-2, as the Vero ΔPVR1 representative for depositing to a cell bank (see also below).

In western blot analysis with an anti-human PVR monoclonal antibody, which was expected to cross-react with AGM PVRs, parental Vero cells exhibited broad bands, with band mobility corresponding to ~60–40 kDa (Fig. 2b). As peptide-N-glycosidase F (PNGase F)-treatment sharpened the bands (Fig. 2c), the observed band broadness was largely due to the heterogeneity of protein glycosylation. Compared with the parental control, the band signal was greatly reduced with Vero PVR1 SKO cells, but not with Vero PVR2 SKO cells. The signal retained with Vero PVR1 SKO cells disappeared with Vero PVR1/2 DKO cells, which indicates that the band represented the PVR2 protein (Fig. 2b,c).

PV-nonsusceptible Vero cell lines. Infectivity of PV in these Vero cell clones was analyzed. The PV Sabin serotypes 1 and 3 strains underwent multiple rounds of infection very efficiently in parental Vero cells, while no virus production was observed in In Vero ΔPVR1/2 cells (Fig. 4a−d, Supplementary Fig. 3e,f). Even when cells were infected with PV’s at a high multiplicity of infection (MOI) of 10, neither virus production nor viral RNA synthesis was detected (Fig. 4e−h, Supplementary Fig. 3g−j). Notably, PVR1 SKO was enough to abrogate PV susceptibility (Fig. 4e−h, Supplementary Fig. 3a,b), while PVR2 SKO had no discernible impact (Fig. 4e−h, Supplementary Fig. 3c,d,g−j), which indicates that PVR1 is the predominant receptor for PV infection in Vero cells. It is currently unknown why the endogenous PVR2 in Vero cells does not seem to serve as a functional PVR, although ectopic overexpression of AGM PVR2 in mouse L cells endows PV-susceptibility to the cells21.

Susceptibility to non-PV viruses. As expected, all the PV1- and/or PV2-disrupted Vero cell clones remained susceptible to measles virus (MV; AIK-C vaccine strain-derived recombinant virus; Supplementary Fig. 4), rubella virus (RV; rHS717AG1 wild strain-derived recombinant virus; Supplementary Fig. 5), and Japanese encephalitis virus (JEV; Nakayama strain; Supplementary Fig. 6), eliminating the possibility of non-specific virus tolerance of these Vero cell clones.

Compared with parental Vero cells, all PVR KO clones retained high susceptibility to MV and RV, with similar time courses in virus production (Supplementary Fig. 4, 5). All PVR KO clones also retained high susceptibility to JEV. However, the JEV titer levels of Vero, ΔPVR1-1, and ΔPVR1-1-derived PV1/2 DKO clones, and PVR2 SKO clones peaked at three days post-infection (Supplementary Fig. 6b,c) while those of ΔPVR1-2 and ΔPVR1/2-2-derived PV1/2 DKO cell clones (except for ΔPVR1/2−6) peaked two days post-infection (Supplementary Fig. 6d). The cause of the different characteristics of Vero ΔPVR1-1 and ΔPVR1-2 clones is unknown.

Among the Vero cell mutant clones established in this study, we chose Vero ΔPVR1-1, Vero ΔPVR2-1, and Vero ΔPVR1/2-1 clones as representative cell lines of Vero PVR1 SKO, Vero PVR2 SKO, and Vero PVR1/2 DKO cell clones, respectively (Supplementary Fig. 2). It should be noted that the phenotypes of the representative cell lines were not due to any clonal effects as other mutant cell lines established in this study broadly exhibited the same phenotypes (Figs. 2, 3, 4 and Supplementary Figs. 3−6). For the global distribution, these representative cell lines have been deposited in the Japanese Collection of Research Bioresources (JCRB) Cell Bank, a non-profit public cell bank in Japan. Of note, the representative cell lines deposited to the cell bank were named Vero ΔPVR1, Vero ΔPVR2, and Vero ΔPVR1/2, respectively, for simplicity (Supplementary Fig. 2). Since GAPIII requires the stricter control of PV, we conducted infection experiments using vaccine PV strains with a lower biorisk than wild-type PV. We verified that these Vero cells are not susceptible to PV using attenuated strains (Fig. 4). Since all PV strains use the same PVR22, the loss of PVR may prevent viral receptor binding and the subsequent entry of virulent wild-type PV strains. When performing transfection experiments using RNA extracted from potentially PV-infectious materials, PVR-deficient Vero cells are still susceptible to the first replication cycle occurring in the cell immediately after viral RNA transfection. The duration for which a genomic deletion or insertion by genome editing technologies is stable or how many repeating cell passages are required for safety currently remain unknown. To ensure quality control, PV deficiency may be confirmed using RNA extracted from potentially PV-infectious materials, PVR2, the loss of PVR may prevent viral receptor binding and the subsequent entry of virulent wild-type PV strains. When performing transfection experiments using RNA extracted from potentially PV-infectious materials, PVR-deficient Vero cells are still susceptible to the first replication cycle occurring in the cell immediately after viral RNA transfection. The duration for which a genomic deletion or insertion by genome editing technologies is stable or how many repeating cell passages are required for safety currently remain unknown. To ensure quality control, PV deficiency may be confirmed using RNA extracted from potentially PV-infectious materials, PVR-deficient Vero cells may strengthen the GAPIII mission. Therefore, we are now attempting to establish stable transfectants of the Vero ΔPVR1/2-1 and ΔPVR1/2-2 cell lines expressing the human signaling lymphocytic

and sequenced them individually. Whereas only one type of sequence was obtained from the PVR1 cDNA set (Supplementary Fig. 1a), two types were obtained from the PVR2 cDNA set (Supplementary Fig. 1b), which indicates that different patterns of SNVs, including synonymous and nonsynonymous mutations, exist between the two alleles of PVR2 gene. Of note, Vero cells are pseudodiploid23.
Figure 2. Generation of PVR1/PVR2 double-knockout (DKO) cell lines. (a) Diagram for construction of PVR1/PVR2 double-deficient cell lines. In the first-round experiment, co-transfection of parental Vero cells with two plasmids expressing the sgRNA crV4 (targeting to PVR1) or crV3 (targeting to PVR2) gave only PVR1 single-knockout (SKO) cell lines as shown (Supplementary Fig. 2). One of the purified cell clones named Vero ΔPVR1-1 was subjected to a second-round experiment, in which the cells were transfected with the crV3-expressing plasmid, and two PVR1/2 DKO cell lines named Vero ΔPVR1/2–1 and Vero ΔPVR1/2–2, respectively, were obtained (see also Supplementary Fig. 2). In another experiment, transfection of Vero cells with the plasmid expressing crV2 (targeting to PVR1) gave a PVR1 SKO cell line named Vero ΔPVR1-2, and transfection of Vero ΔPVR1-2 cells with the crV3-expressing plasmid gave four PVR1/2 DKO cell lines: Vero ΔPVR1/2–3, Vero ΔPVR1/2–4, Vero ΔPVR1/2–5, and Vero ΔPVR1/2–6 (Supplementary Fig. 2). For construction of PVR2 SKO cells, Vero JCRB9013 cells were transfected with the crV3-expressing plasmid, and two mutant cell lines, Vero ΔPVR2-1 and Vero ΔPVR2-2, were obtained (see also Supplementary Fig. 2). (b) Fifteen-microgram aliquots of protein samples prepared from the Vero cell line (Vero), two PVR1 SKO cell lines (ΔPVR1-1 and ΔPVR1-2), six PVR1/PVR2 DKO cell lines (ΔPVR1/2–1, ΔPVR1/2–2, ΔPVR1/2–3, ΔPVR1/2–4, ΔPVR1/2–5, and ΔPVR1/2–6), and two PVR2 SKO cell lines (ΔPVR2-1 and ΔPVR2-2) were subjected to western blot analysis using the anti-PVR/CD155 rabbit monoclonal antibody D3G7H (upper panel). Loading control GAPDH was detected with the anti-GAPDH rabbit monoclonal antibody 14C1 (lower panel). (c) After removal of N-linked glycans, protein samples equivalent to 5 µg of cell lysate were subjected to western blot analysis. PNGase F-untreated controls of Vero and ΔPVR2-1 cell-derived samples are shown in the leftmost and rightmost lanes, respectively, in the panel.
activation molecule in order to isolate the measles virus. When an outbreak of an emerging and re-emerging infectious disease occurs, the identification of the causative pathogen is crucial. Additionally, in vitro pathogen culture systems are invaluable for fully characterizing the pathogen and the development of anti-pathogenic drugs. The present study provides evidence that when Vero ΔPVR1/2 cells are employed as host cells for non-PV viruses, the resultant cell culture can be excluded from classification as “potentially PV-infected materials”. Thus, Vero ΔPVR1/2 cells may serve as an ideal replacement of standard Vero cells to isolate emerging/re-emerging viruses without the risk of generating potentially PV-infected materials, which is in alignment with the WHO GAPIII mission. A study on PVR-disrupted mutant cell lines of human cervical cancer-derived HeLa and rhabdomyosarcoma-derived RD-A cells with a similar aim, to be used mainly for non-polio enterovirus isolation, was recently published after the submission of this manuscript 23.

Methods

Cells and cell culture. Vero cells (JCRB9013) were obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank. Note that the quality of the cells was assured by standard tests of the cell bank. Cells were cultivated in a normal growth medium consisting of Eagle's minimal essential medium (MEM; Fujifilm Wako Pure Chemical Co., Osaka, Japan) supplemented with 5% heat-inactivated fetal bovine serum (FBS; Sigma-Aldrich, MO, USA) and penicillin–streptomycin (Fujifilm Wako Pure Chemical Co.), at 37 °C and under an atmosphere of 5% CO2 and 100% humidity. Cells were detached with AccuMax dissociation solution (Innovative Cell Technologies, CA, USA) and passaged at a split ratio of 1:5.

Cell growth curve and microscopy. Cells were seeded at a density of 1 × 10^4 cells/well in a 24-well plate (Corning Inc, N.Y., USA) and cultured for seven days in normal growth medium. Cells were detached with
AccuMax and stained with trypan blue solution (Thermo Fisher Scientific), and live cells in three independent wells were counted using a Countess II Automated Cell Counter (Thermo Fisher Scientific). To examine cell morphologies, cells were photographed using a BZ-X710 All-in-One Fluorescence Microscope (Keyence, Osaka, Japan).

cDNA sequencing of Vero-PVR1 and Vero-PVR2. RNA was extracted from Vero cells using the NucleoSpin RNA kit (Takara Bio Inc.), and cDNA was synthesized with the PrimeScript 1st strand cDNA Synthesis Kit (Takara Bio Inc.). Full-length Vero-PVR1 and Vero-PVR2 cDNA was amplified with the Easy-A High Fidelity PCR Cloning Enzyme (Agilent Technologies, CA, USA), and cloned into T-vector pMD20 (Takara Bio Inc.). To amplify Vero-PVR1, cloning primers 1-Fw; 5′-ATG GCC CGA ACC ATG GCC GCC GCA TG-3′ and 1/2-
CCL-23), a HeLa sub-line (ATCC, VA, USA). Viral RNA copy numbers in the culture fluid was also measured

5% CO2 humid atmosphere with MEM (Thermo Fisher Scientific) containing 2% FBS (Biowest, Nuaillé, France)

lysate as described in Methods and treated with peptide-N-glycosidase F (PNGase F; New England Biolabs, MT,

or 0.01. After 1 h incubation at 35 °C, the cells were washed three times with PBS (−) and cultured at 35 °C in a

or 0.01. After 1 h incubation at 35 °C, the cells were washed three times with PBS (−) and cultured at 35 °C in a

To remove N-linked glycans, 25 µg of protein was precipitated from cell

and penicillin–streptomycin (Cosmo Bio Co., Tokyo, Japan). At appropriate intervals, cells were dissociated by

precipitated proteins were dissolved and denatured in modified Laemmli sample buffer (Bio-Rad, CA, USA),

of protein was electrophoresed on 15% e-PAGEI sodium dodecyl sulfate polyacrylamide gel electrophoresis

precipitated proteins were dissolved and denatured in modified Laemmli sample buffer (Bio-Rad, CA, USA),

protein assay kit (Takara Bio Inc.). Cell lysate containing the same amount of protein was mixed with 10 vol-

ysisate as described in Methods and treated with peptide-N-glycosidase F (PNGase F; New England Biolabs, MT,

Deglycosylation of proteins. To remove N-linked glycans, 25 µg of protein was precipitated from cell

PV infection and titration. Vero and PVR KO cells seeded in a 12-well plate were infected with PV Sabin

immunosignals were detected as described in Methods and treated with peptide-N-glycosidase F (PNGase F; New England Biolabs, MT, USA) according to the manufacturer's instructions.

DNA sequencing of Vero-PVR1 and Vero-PVR2. Genomic DNA was isolated from Vero cells using the

Construction of a vector for the CRISPR/Cas9 system. Guide sequences containing the target

Western blotting. All procedures were performed at 4 °C or on ice, unless otherwise noted. Cells were

DNA sequences were cloned into the BsmBI site of the pSELECT-CRISPR cas9 plasmid as described previously24,25.

The target sequences specific for Vero-PVR1 and -PVR2 are shown in Fig. 1b. Vero cells were transfected with the

Genomic DNA was isolated from Vero cells using the

PVR2 has a nucleotide polymorphism at its
designed because our genomic DNA sequence analysis showed that

PVR2 has a nucleotide polymorphism at its
designed because our genomic DNA sequence analysis showed that

To remove N-linked glycans, 25 µg of protein was precipitated from cell

precipitated proteins were dissolved and denatured in modified Laemmli sample buffer (Bio-Rad, CA, USA),

precipitated proteins were dissolved and denatured in modified Laemmli sample buffer (Bio-Rad, CA, USA),

of protein was electrophoresed on 15% e-PAGEI sodium dodecyl sulfate polyacrylamide gel electrophoresis

precipitated proteins were dissolved and denatured in modified Laemmli sample buffer (Bio-Rad, CA, USA),

of protein was electrophoresed on 15% e-PAGEI sodium dodecyl sulfate polyacrylamide gel electrophoresis

Received: 19 August 2020; Accepted: 9 March 2021
Published online: 24 March 2021

Rv; 5′-CCT TGT GCC CTC TGT CTG TGG ATC CTG-3′ were used. For Vero-PVR2, two primer sets were
designed because our genomic DNA sequence analysis showed that PVR2 has a nucleotide polymorphism at its
5′ terminus (Supplementary Fig. 1b). One of the primer sets for Vero-PVR2 was cloning primer 2G-Fw (5′-ATG
GCC GCC GCA TGG CTC CGG CTG CTG-3) and 1/2-Rv (5′-CCT TGT GCC CTC TGT CTG TGG ATC CTG-3′), and the other primer set was 2A-Fw (5′-ATG GCC GCC GCA TGG CTC CGG CTG CTA-3′) and 1/2-Rv (5′-CCT TGT GCC CTC TGT CTG TGG ATC CTG-3′). The nucleotide sequences were determined by

DNA sequencing of Vero-PVR1 and Vero-PVR2. Genomic DNA was isolated from Vero cells using the

NucleoSpin Tissue kit (Takara Bio Inc., Shiga, Japan). To determine the sequence of the N-terminal PVR1- and

PVR2-coding regions, the genomic DNA served as a template for PCR with Tks Gflex DNA polymerase (Takara
Bio Inc.) using the following primer sets: primer set-1 for PVR1 (primer 1-Fw; 5′-ATC TGT CCC ATC ACG
AGT TGA-3′, primer 1-Rv; 5′-AAC CCC GGG GCA GAG ATG-3′), and primer set-2 for PVR2 (primer 2-Fw;
5′-CTC GCC TCA CTG GTC TGG AAC-3′, primer 2-Rv; 5′-CTG CAT GCG GAG CTG GGA GC-3′). The resultant PCR products were subjected to Sanger DNA sequencing.

sequences were cloned into the BsmBI site of the pSELECT-CRISPR cas9 plasmid as described previously24,25.

The target sequences specific for Vero-PVR1 and -PVR2 are shown in Fig. 1b. Vero cells were transfected with the

Western blotting. All procedures were performed at 4 °C or on ice, unless otherwise noted. Cells were

was washed with phosphate buffered saline (PBS) three times, removed from the plates using cell scrapers (IWAKI,
Tokyo, Japan) in 1 ml of PBS, and centrifuged at 10,000×g for 3 min. The cell pellets were stored at -30 °C until

analysis. Each frozen pellet was thawed on ice and lysed for 10 min with 200 µl of 100 mM Tris–HCl (pH 7.0)
buffer containing 0.5% NP-40, 0.5% sodium deoxycholate, 10 mM ethylenediaminetetraacetic acid (EDTA),
and 100 mM NaCl. After centrifugation at 1,000 × g for 3 min to remove insoluble debris, the supernatant frac-
tion was collected as cell lysate. Protein concentrations of cell lysates were measured using a bicinchoninic acid
protein assay kit (Takara Bio Inc.). Cell lysate containing the same amount of protein was mixed with 10 vol-
umes of methanol and then centrifuged at 20,000 × g for 30 min to precipitate proteins. After drying by air, the

 Deglycosylation of proteins. To remove N-linked glycans, 25 µg of protein was precipitated from cell

Western blotting. All procedures were performed at 4 °C or on ice, unless otherwise noted. Cells were

was washed with phosphate buffered saline (PBS) three times, removed from the plates using cell scrapers (IWAKI,
Tokyo, Japan) in 1 ml of PBS, and centrifuged at 10,000×g for 3 min. The cell pellets were stored at -30 °C until

analysis. Each frozen pellet was thawed on ice and lysed for 10 min with 200 µl of 100 mM Tris–HCl (pH 7.0)
buffer containing 0.5% NP-40, 0.5% sodium deoxycholate, 10 mM ethylenediaminetetraacetic acid (EDTA),
and 100 mM NaCl. After centrifugation at 1,000 × g for 3 min to remove insoluble debris, the supernatant frac-
tion was collected as cell lysate. Protein concentrations of cell lysates were measured using a bicinchoninic acid
protein assay kit (Takara Bio Inc.). Cell lysate containing the same amount of protein was mixed with 10 vol-
umes of methanol and then centrifuged at 20,000 × g for 30 min to precipitate proteins. After drying by air, the

precipitated proteins were dissolved and denatured in modified Laemmli sample buffer (Bio-Rad, CA, USA),
containing100 mM dithiothreitol rather than 5% 2-mercaptoethanol, by boiling for 10 min. Fifteen micrograms of protein was electrophoresed on 15% e-PAGEI sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels (ATTO, Tokyo, Japan) and transferred to polyvinylidene difluoride membranes (ATTO). The anti-PVR/CD155 rabbit monoclonal antibody D3G7H (Cell Signaling Technology, MA, USA; 0.1 µg/ml) and anti-GAPDH rabbit monoclonal antibody 14C10 (Cell Signaling Technology; 0.1 µg/ml) were diluted with Can Get Signal Immunoreaction Enhancer Solution (TOYOBO Life Science, Osaka, Japan) and used as primary antibodies. A horseradish peroxidase (HRP)-labeled anti-rabbit IgG antibody (Jackson ImmunoResearch, PA, USA; 0.7 µg/ml) in Tris-buffered saline with 0.05% Tween 20 was used as a secondary antibody. Proteins were detected by Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore, MA, USA) and a LAS-3000 mini chemiluminescence imaging system (Fujifilm, Tokyo, Japan) with ImageGauge software (Fujifilm).

Deglycosylation of proteins. To remove N-linked glycans, 25 µg of protein was precipitated from cell

PV infection and titration. Vero and PVR KO cells seeded in a 12-well plate were infected with PV Sabin
1 and Sabin 3 strains (National Institute for Biological Standards and Control, Hertfordshire, UK) at MOI of 10
or 0.01. After 1 h incubation at 35 °C, the cells were washed three times with PBS (−) and cultured at 35 °C in a
5% CO2 humid atmosphere with MEM (Thermo Fisher Scientific) containing 2% FBS (Biovest, Nuillé, France)
and penicillin–streptomycin (Cosmo Bio Co., Tokyo, Japan). At appropriate intervals, cells were dissociated by
pipetting and collected together with culture supernatants as the culture fluid. The culture fluid was subjected
to three freeze–thaw cycles and then centrifuged at 1,000 × g for 5 min to remove debris. Virus titer was deter-
mined by 50% end-point dilution assay (50% tissue culture infectious dose, TCID50) using HEp-2 cells (ATCC
CCL-23), a HeLa sub-line (ATCC, VA, USA). Viral RNA copy numbers in the culture fluid was also measured
by real-time reverse transcription-PCR4,27.
References

1. Nomoto, A., Koike, S. & Aoki, J. Tissue tropism and species specificity of poliovirus infection. Trends Microbiol. 2, 47–51. https://doi.org/10.1016/0966-842x(94)90125-2 (1994).

2. Alonge, O. What can over 30 years of efforts to eradicate polio teach us about global health?. BMC Public Health 20(2), 1177. https://doi.org/10.1186/s12889-020-09198-z (2020).

3. Shaghaghi, M. et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection: systematic review of over 5 decades of data. Vaccine 36, 1711–1719. https://doi.org/10.1016/j.vaccine.2018.02.059 (2018).

4. Macklin, G. R. et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 368, 401–405. https://doi.org/10.1126/science.aba1238 (2020).

5. The World Health Organization. WHO Global Action Plan to Minimize Poliovirus Facility-Associated Risk After Type-Specific Eradication of Wild Polioviruses and Sequential Cessation of Oral Polio Vaccine Use (WHO Press, Cleveland, 2015).

6. Yasumura, Y. & Kawakita, Y. in VERO Cells: Origin, Properties and Biomedical Applications (eds Simizu B. & T. Terasima) 1–19 (Department of Microbiology School of Medicine Chiba University, 1988).

7. Osada, N. Novel endogenous simian retroviral integrations in Vero cells: implications for quality control of a human vaccine cell substrate. Sci. Rep. 8, 644. https://doi.org/10.1038/s41598-017-18934-2 (2018).

8. Sakuma, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953–1966. https://doi.org/10.1056/NEJMoa030781 (2003).

9. Drosten, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967–1976. https://doi.org/10.1056/NEJMoa030747 (2003).

10. Matsuyma, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U.S.A. 117, 7001–7003. https://doi.org/10.1073/pnas.2002589117 (2020).

11. Pires de Mello, C. P., Drusano, G. L., Rodriquez, J. L., Kaushik, A. & Brown, A. N. Antiviral effects of clinically-relevant interferon-alpha and ribavirin regimens against dengue virus in the hollow fiber infection model (HFIM). Viruses https://doi.org/10.3390/v10060317 (2018).

12. Ellis, D. S. et al. Ebola and Marburg viruses: II. Thier development within Vero cells and the extra-cellular formation of branched and torus forms. J. Med. Virol. 4, 213–225 (1979).

13. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953–1966. https://doi.org/10.1056/NEJMoa030781 (2003).

14. Drosten, C. et al. Isolation of the SARS-CoV-2 virus in cell culture by using a epithelial cell line. N. Engl. J. Med. 383, 788–796. https://doi.org/10.1056/NEJMoa2003570 (2020).

15. Montagnon, B. J. & Vincent-Falquet, J. C. Experience with the Vero cell line. Dev. Biol. Stand. 93, 119–123 (1998).

16. Montomoli, E. et al. Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine. J. Virol. Methods 259, 74–80. https://doi.org/10.1016/j.jvirmeth.2018.06.009 (2018).

17. Warren, W. C. et al. The genome of the vervet (Chlorocebus aethiops sabaeus). Genome Res. 25, 1921–1933. https://doi.org/10.1101/gr.192922.115 (2015).

18. Koike, S. et al. A second gene for the African green monkey poliovirus receptor that has no putative N-glycosylation site in the functional N-terminal immunoglobulin-like domain. J. Virol. 66, 7059–7066 (1992).

Acknowledgements

We are grateful to Dr. Satoshi Koike (Neurovirology Project, Tokyo Metropolitan Institute of Medical Science) for his expertise in poliovirus research and invaluable suggestions. We would also like to acknowledge Drs. Hiroyuki Shimizu and Masamichi Muramatsu (Department of Virology 2, NIID) for their helpful comments on the public health of polio and the WHO Polio Global Specialized Laboratory. We thank Dr. Martin Cheung from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.

Author contributions

K.H. and M.T. designed research studies. Y.O.-N. and T.Y. designed sgRNAs. Y.O.-N. isolated PVR-disrupted cell lines and performed cell experiments. Ky.S. and Y.O.-N. performed JEV experiments, and Ke.S. performed all other viral experiments. All authors interpreted the data. K.H., Y.O.-N., and Ke.S. drafted the manuscript and all authors approved the final version of manuscript.

Funding

This research was supported by AMED-CREST (JP19gm0910005j0005 to K.H.), JSPS KAKENHI (JP17H04003 to K.H.), AMED (20k0108086j0202 to M.T.), and TERUMO LIFE SCIENCE FOUNDATION (to Ke.S.).
